Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

BACKGROUND: Oral oncolytic therapies have improved survival in hematologic cancers, such as chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and multiple myeloma (MM), which are now being managed like chronic conditions. However, compared with other cancers, there is a lack of studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dashputre, Ankur A., Gatwood, Katie S., Gatwood, Justin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391134/
https://www.ncbi.nlm.nih.gov/pubmed/32011965
http://dx.doi.org/10.18553/jmcp.2020.26.2.186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391134/
https://www.ncbi.nlm.nih.gov/pubmed/32011965
http://dx.doi.org/10.18553/jmcp.2020.26.2.186

Ejemplares similares